🔗 Share this article

While the US undertakes sweeping revisions to its immunization recommendations, an unexpected name has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who initially gained attention by casting doubt on coronavirus vaccines in the global health crisis and has concentrated on potential fatalities following COVID-19 vaccination in her brief time at the FDA.

Scheduled Overhauls to Pediatric Vaccine Program

Health officials were set to announce sweeping revisions to the childhood vaccination calendar recently, synchronizing the US with the Danish immunization schedule, sources say – a major change that would put the US out of step with much of the international standard with insufficient data for improved outcomes. The planned update has been pushed back until the next year.

In place of Vinay Prasad, Høeg is listed to speak at the meeting. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the center this year.

Consolidating Power at the Regulatory Body

The acting appointment may indicate a closer partnership between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad solidify control at the regulatory agency – and it points to a increased emphasis upon rolling back already-approved vaccines at the FDA.

The new acting director has repeatedly called for ending certain pediatric shot schedules in the US to become more like Denmark's approach, a society with universal health coverage and a population about the size of the state of Wisconsin.

To date comments, she has continued to focus on vaccines – usually the purview of Dr. Prasad, head of the FDA’s CBER – instead of drug regulation.

Doubts Over Qualifications

Høeg has no obvious experience in drug development, approval processes or administrative roles, which has been typical for former directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have the necessary background” for leading the CDER, remarked Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in managing a large organization. She lacks background in industry regulation.”

Previous commissioners of the center would “be deeply familiar with laws and regulations and the science of medication creation”, said Dr. Janet Woodcock. “Frankly, she lacks the sort of resume that prior appointees who led CBER have had.”

This division has an immense portfolio at the agency, the former commissioner emphasized.

“The public just pays attention on the novel medication approvals, but the generic program approves thousands of off-brand pharmaceuticals. There is also a biosimilars program, over-the-counter program and so forth, and every single one must be managed,” Woodcock noted. “The responsibility you neglect, that is the part that I always told people is going to cause problems.”

There is also, a significant administrative element to the role, which manages over 5,000 employees. “It’s a huge management job, if you perform it correctly,” the former official said.

Agency Reaction and Disputed Policies

When asked about questions about Dr. Høeg's credentials and whether this appointment indicates more teamwork among FDA leaders on immunizations, a spokesperson stated that the “inquiries are based on flawed assumptions”.

“Her experience matches the responsibilities of her role,” the official explained, citing the time Dr. Høeg spent guiding the agency head on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As acting director, Dr. Høeg assumes responsibility for the agency head's recently launched expedited review system, a controversial one-day therapy clearance system that reportedly worried her predecessors. “How are these drugs being picked for this voucher program? Who makes the choices?” Dr. Howard questioned. “There’s a lot of lack of transparency going on at the FDA right now.”

In general, he said, “the agency seems to be moving towards less stringent rules of all drugs, with the exception of immunizations.”

Documented Track Record on Vaccines

Concerning vaccines, Høeg has a clearer, if concerning, track record, Howard said. She authored a study using non-validated crowd-sourced reports to estimate the incidence of myocarditis following COVID-19 vaccination. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccines are pose a greater threat than they are.

Among her “desired changes” for the new administration featured changing rules for recently developed shots and ending “non-essential” vaccines, she remarked post-election on a podcast. At the FDA, Høeg has according to sources floated the idea of preventing young men from receiving COVID-19 vaccines.

“She is an thorough true believer who starts off with her beliefs and reverse-engineers to fit the evidence in a very misleading, dishonest fashion,” Dr. Howard argued.

Consolidating Power and a “Campaign of Retribution”

Høeg joined other dissenters, {like|